Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
Walle T, Bajaj S, Kraske JA, Rösner T, Cussigh CS, Kälber KA, Müller LJ, Strobel SB, Burghaus J, Kallenberger SM, Stein-Thöringer CK, Jenzer M, Schubert A, Kahle S, Williams A, Hoyler B, Zielske L, Skatula R, Sawall S, Leber MF, Kunes RZ, Krisam J, Fremd C, Schneeweiss A, Krauss J, Apostolidis L, Berger AK, Haag GM, Zschäbitz S, Halama N, Springfeld C, Kirsten R, Hassel JC, Jäger D; NCT ANTICIPATE Investigators; Ungerechts G. Walle T, et al. Among authors: rosner t. Nat Cancer. 2022 Sep;3(9):1137. doi: 10.1038/s43018-022-00420-y. Nat Cancer. 2022. PMID: 35840692 Free PMC article. No abstract available.
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
Walle T, Bajaj S, Kraske JA, Rösner T, Cussigh CS, Kälber KA, Müller LJ, Strobel SB, Burghaus J, Kallenberger SM, Stein-Thöringer CK, Jenzer M, Schubert A, Kahle S, Williams A, Hoyler B, Zielske L, Skatula R, Sawall S, Leber MF, Kunes RZ, Krisam J, Fremd C, Schneeweiss A, Krauss J, Apostolidis L, Berger AK, Haag GM, Zschäbitz S, Halama N, Springfeld C, Kirsten R, Hassel JC, Jäger D; NCT ANTICIPATE Investigators; Ungerechts G. Walle T, et al. Among authors: rosner t. Nat Cancer. 2022 Sep;3(9):1039-1051. doi: 10.1038/s43018-022-00398-7. Epub 2022 Jun 17. Nat Cancer. 2022. PMID: 35715501 Free PMC article.
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T, Lutz S, Münnich IA, Windisch R, Hilger P, Herold T, Tahiri N, Banck JC, Weigert O, Moosmann A, von Bergwelt-Baildon M, Flamann C, Bruns H, Wichmann C, Baumann N, Valerius T, Schewe DM, Peipp M, Rösner T, Humpe A, Kellner C. Zeller T, et al. Among authors: rosner t. Front Immunol. 2022 Oct 27;13:929339. doi: 10.3389/fimmu.2022.929339. eCollection 2022. Front Immunol. 2022. PMID: 36389667 Free PMC article.
The Other Dimension-Tuning Hole Extraction via Nanorod Width.
Rosner T, Pavlopoulos NG, Shoyhet H, Micheel M, Wächtler M, Adir N, Amirav L. Rosner T, et al. Nanomaterials (Basel). 2022 Sep 25;12(19):3343. doi: 10.3390/nano12193343. Nanomaterials (Basel). 2022. PMID: 36234471 Free PMC article.
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
Gehlert CL, Rahmati P, Boje AS, Winterberg D, Krohn S, Theocharis T, Cappuzzello E, Lux A, Nimmerjahn F, Ludwig RJ, Lustig M, Rösner T, Valerius T, Schewe DM, Kellner C, Klausz K, Peipp M. Gehlert CL, et al. Among authors: rosner t. Front Immunol. 2022 Aug 31;13:957874. doi: 10.3389/fimmu.2022.957874. eCollection 2022. Front Immunol. 2022. PMID: 36119088 Free PMC article.
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Baumann N, Arndt C, Petersen J, Lustig M, Rösner T, Klausz K, Kellner C, Bultmann M, Bastian L, Vogiatzi F, Leusen JHW, Burger R, Schewe DM, Peipp M, Valerius T. Baumann N, et al. Among authors: rosner t. Front Immunol. 2022 Aug 16;13:949140. doi: 10.3389/fimmu.2022.949140. eCollection 2022. Front Immunol. 2022. PMID: 36052078 Free PMC article.
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM. Vogiatzi F, et al. Among authors: rosner t. Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364. Blood Adv. 2022. PMID: 35820018 Free PMC article.
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
Müller K, Vogiatzi F, Winterberg D, Rösner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MP, Brüggemann M, Cario G, Schrappe M, Kulozik AE, Eckert C, Bergmann AK, Bornhauser B, Bourquin JP, Valerius T, Peipp M, Kellner C, Schewe DM. Müller K, et al. Among authors: rosner t. Blood. 2022 Jul 7;140(1):45-57. doi: 10.1182/blood.2021014485. Blood. 2022. PMID: 35452517 Free article.
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.
Evers M, Rösner T, Dünkel A, Jansen JHM, Baumann N, Ten Broeke T, Nederend M, Eichholz K, Klausz K, Reiding K, Schewe DM, Kellner C, Peipp M, Leusen JHW, Valerius T. Evers M, et al. Among authors: rosner t. Blood Adv. 2021 Oct 12;5(19):3807-3820. doi: 10.1182/bloodadvances.2021004598. Blood Adv. 2021. PMID: 34525171 Free PMC article.
82 results